LDLR and neoplasm: PCSK9 plays a crucial role in cholesterol metabolism by regulating low-density lipoprotein receptor (LDLR) degradation; however, emerging evidence suggests that it may also influence tumor progression through its effects on lipid homeostasis, inflammation, and immune modulation.